002294 Stock Overview
Shenzhen Salubris Pharmaceuticals Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Shenzhen Salubris Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥31.73 |
| 52 Week High | CN¥38.10 |
| 52 Week Low | CN¥23.50 |
| Beta | 0.69 |
| 11 Month Change | -3.29% |
| 3 Month Change | 8.15% |
| 1 Year Change | -3.41% |
| 33 Year Change | 12.64% |
| 5 Year Change | 72.73% |
| Change since IPO | 6.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| 002294 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 4.5% | -1.5% | -2.1% |
| 1Y | -3.4% | -9.4% | 2.8% |
Return vs Industry: 002294 exceeded the CN Pharmaceuticals industry which returned -9.4% over the past year.
Return vs Market: 002294 underperformed the CN Market which returned 2.8% over the past year.
Price Volatility
| 002294 volatility | |
|---|---|
| 002294 Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 002294 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002294's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 3,517 | Jie Yan | www.salubris.com |
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also provides interventional medical devices for therapy of cardiovascular and cerebrovascular diseases, peripheral blood vessels, structural heart diseases, electrophysiology, and cardiac rhythm management.
Shenzhen Salubris Pharmaceuticals Co., Ltd. Fundamentals Summary
| 002294 fundamental statistics | |
|---|---|
| Market cap | CN¥35.37b |
| Earnings (TTM) | CN¥610.61m |
| Revenue (TTM) | CN¥3.91b |
57.9x
P/E Ratio9.0x
P/S RatioIs 002294 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002294 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.91b |
| Cost of Revenue | CN¥1.12b |
| Gross Profit | CN¥2.79b |
| Other Expenses | CN¥2.18b |
| Earnings | CN¥610.61m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.55 |
| Gross Margin | 71.37% |
| Net Profit Margin | 15.62% |
| Debt/Equity Ratio | 0.7% |
How did 002294 perform over the long term?
See historical performance and comparison